Navigation Links
NicOx' Naproxcinod ABPM Data Presented at American Heart Association
Date:11/7/2007

se compounds in the reverse order. Subjects received a 2 week placebo wash-out before and in between the active treatment periods. Eligible subjects were between 50 and 75 years of age, in order to be representative of the osteoarthritis population, and 71.8% were over 65 years of age. Eligible subjects had controlled hypertension, defined as SBP inferior to 150 mmHg and/or DBP inferior to 95 mmHg and were treated for their hypertension by drugs from no more than 2 different antihypertensive drug classes at stable doses at screening. Eligible patients were not current NSAID users.

ABPM involves using a portable device to independently measure and record blood pressure at frequent intervals over a 24-hour period with minimal disruption of the subject's daily activity. In this trial, a 24-hour ABPM was performed at the start and following each of the two active treatment periods. During the 24-hour period, blood pressure measurements were taken at 20-minute intervals between 6:00 am and 10:00 pm and every hour from 10:01 pm to 5:59 am. In total four 24-hour ABPM measurements were taken per subject.

About naproxcinod

Naproxcinod, NicOx' lead investigational product, is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Results from the first pivotal phase 3 study (the 301 study) showed that naproxcinod has superior efficacy compared to placebo and no detrimental effect on blood pressure, in contrast to the existing anti-inflammatory agent naproxen. The two remaining pivotal phase 3 trials for naproxcinod are currently ongoing (302 and 303) and patients are undergoing standardized blood pressure measurements at each visit to the treatment center in these studies (Office Blood Pressure Measurements, OBPM). The Company expects to report the 302 and 303 efficacy results in mid-2008 and will conduct a predefined statistical analysis on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), follow
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... been named the 2013 Life Science Firm of the Year ... (TCM).  Vanda was honored at the TCM,s 25 th ... , Maryland.  The Tech Awards Celebration recognizes the leaders and ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
(Date:5/25/2013)... Forney, United States (PRWEB) May 25, 2013 ... oldest and largest underground shelter company in the ... and composite underground structures for over 35 years. ... of PROTECTION, U.S. Handbook of NBC Weapon Fundamentals ... is the United States’ bible on shelter engineering. ...
(Date:5/25/2013)... 25, 2013 Providing patients with their best ... team of weight management professionals. But, aside from educating patients ... Diet Doc’s hCG diets also provide patients, who ... childhood like bullying, more control over their lives by achieving ... with the underlying factors of weight gain derived from earlier ...
(Date:5/25/2013)... On May 20, 2013 the Sydney Morning ... discuss or plan for their eventual demise, but it is ... a Must-Do List to help people properly arrange for their ... personal fact sheet.” , While not a formal document, this ... data. It may include a summary of assets, debts, ...
(Date:5/25/2013)... 2013 The latest report from ... bowel syndrome (IBS) to bloating, constipation, diarrhea and ... long-lasting, embarrassing, frustrating and difficult health issues to ... health have provided a cure for these ... contributing to digestive health issues, a healthy diet ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 On May ... brain cancer research and advocacy, comments on a new ... that shows incorporating cold atmospheric plasma into brain cancer ... , According to a Science Daily article, ... (MPE), biologists and physicians demonstrated the “synergistic effect of ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2
... Friday 18 June 2010: There is significant disparity between ... access to biological treatments for rheumatoid arthritis (RA), according ... presented today at EULAR 2010, the Annual Congress of ... findings from a separate study show that RA patients ...
... Angeles, CA (June 18, 2010) Leading academic and ... new online resource that will put the spotlight on ... ( http://www.sagepub.com/sageinsight ) links to highly topical articles from ... platform, SAGE Journals Online. Drawn from both new and ...
... ... has recently received a grant award of $100,000 over three years from The Jewish Fund ... ... (MPCC) has recently received a grant award of $100,000 over three years from The Jewish ...
... ... InsuringCT.com as ’40 Under 40’ recipients. , ... Westport, CT (PRWEB) June 18, 2010 -- Siblings Tim Tracy Jr. and Sheena ... award. The annual award recognizes 40 successful business leaders under the age of 40 ...
... ... Systems will showcase new consulting services and advanced software tools at the Healthcare Financial ... , ... 2010 -- 3M Health Information Systems will showcase new consulting services and advanced software ...
... dropped, study found , FRIDAY, June 18 (HealthDay News) ... reduce consumption and help lower levels of obesity and ... , Researchers examined what happened during a time period ... Boston increased the price of regular soft drinks by ...
Cached Medicine News:Health News:Country economy is a stronger predictor of therapy initiation 2Health News:The Jewish Fund Awards Mercy Primary Care Center $100,000 Over Three Years for Chronic Disease Management of Hypertensive Patients 2Health News:3M to Exhibit at Healthcare Financial Management Association (HFMA) Annual Conference 2Health News:People May Skip Soft Drinks Rather Than Pay More 2
Cold light source single outlet....
Cold light source single outlet....
Cold light source single outlet....
Cold light source triple outlet....
Medicine Products: